EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint grants a small inducement stock option award to a new employee with a four-year vesting schedule and 10-year term.

Rhea-AI Summary

EyePoint (EYPT) granted a non-statutory stock option inducement award to one new employee under NASDAQ Listing Rule 5635(c)(4).

The grant, made outside EyePoint’s 2023 Long-Term Incentive Plan, covers options to purchase up to an aggregate of 3,000 shares of common stock, issued on September 15, 2026. The options have an exercise price of $3.66 per share, equal to the closing price of EyePoint’s common stock on that date, and a ten-year term. Vesting occurs over four years: 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the next three years, subject to the employee’s continued service.

Key Figures

Inducement option shares: 3,000 shares Exercise price: $3.66 per share Option term: 10 years +1 more

Inducement option shares

3,000 shares

Granted to one new employee

Exercise price

$3.66 per share

Equal to the September 15, 2026 closing price

Option term

10 years

Term of the inducement stock options

Vesting period

4 years

25% vests after one year; remainder vests monthly

Key Terms

non-statutory stock options, nasdaq listing rule 5635(c)(4)

2 terms

non-statutory stock options financial

"granted non-statutory stock options to new employee"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 3,000 shares of EyePoint common stock to one new employee. The stock options were granted on September 15, 2026. The grant was approved by the Compensation Committee and made as an inducement material to the employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $3.66 per share, the closing price of EyePoint’s common stock on September 15, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data for wet AMD was disclosed in August 2026 for LUGANO, and further data from LUCIA is expected in the fourth quarter of 2026. Topline data for DME is expected in the fourth quarter of 2027.

The Company is committed to partnering with the retinal community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:
Robin Garner
EyePoint, Inc.
ir@eyepoint.bio

Media:
Helen O’Gorman
FTI Consulting
media@eyepoint.bio